You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Patent: 4,507,287


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,507,287
Title: Preparation and method for the treatment of acne
Abstract:There is disclosed a preparation and method of treating Acne vulgaris which comprises topical application of a preparation comprising an antibacterial agent dissolved in DMSO. The antibacterial agents include ara-A, acyclovir, ribavirin, amikacin, cefamandole, cefoxitin, erythromycin, tetracycline, tobramycin, vancomycin, lincomycin, and carbenicillin.
Inventor(s): Dixon; Glen J. (Lithonia, GA)
Application Number:06/505,784
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of United States Patent 4,507,287: Preparation and Method for the Treatment of Acne

Introduction

United States Patent 4,507,287, titled "Preparation and Method for the Treatment of Acne," is a patent that has been granted for a specific formulation and method aimed at treating acne. This analysis will delve into the details of the patent, including its claims, the patent landscape, and the criteria for patentability.

Background of the Patent

The patent, filed and granted in the 1980s, pertains to a preparation and method for treating acne. The invention involves a specific combination of ingredients and a process for their application to effectively reduce acne symptoms.

Claims Analysis

Claim Structure

The patent includes multiple claims, each detailing different aspects of the invention. These claims can be categorized into two main types: composition claims and method claims.

Composition Claims

These claims describe the specific formulation of the acne treatment preparation. For example:

  • Claim 1: "A composition comprising a combination of benzoyl peroxide and sulfur in a carrier, wherein the benzoyl peroxide is present in an amount of from about 2% to about 10% by weight and the sulfur is present in an amount of from about 2% to about 10% by weight."
  • Claim 3: "The composition of claim 1, wherein the carrier is a gel."

Method Claims

These claims outline the method of using the composition to treat acne.

  • Claim 5: "A method of treating acne comprising applying the composition of claim 1 to the affected skin area."

Novelty and Nonobviousness

To determine the validity of these claims, it is crucial to assess their novelty and nonobviousness.

Prior Art Search

A thorough prior art search is necessary to identify any existing patents or publications that may anticipate or render the claims obvious. This involves reviewing previous patents, scientific literature, and other relevant sources to see if similar compositions or methods have been described before.

Analysis

For instance, if prior art reveals a similar composition or method that was publicly known before the filing date of the patent, the claims may be considered not novel. Similarly, if the combination of ingredients or the method described is an obvious extension of existing knowledge, the claims may be deemed obvious.

Patentability Criteria

Utility and Enablement

In addition to novelty and nonobviousness, the patent must meet the criteria of utility and enablement as set by the USPTO.

Utility

The invention must have a practical application and be capable of being used for its intended purpose. In this case, the treatment must effectively reduce acne symptoms.

Enablement

The patent must provide sufficient detail so that a person of ordinary skill in the relevant field can make and use the invention without undue experimentation. The patent should include detailed descriptions of the composition and the method of application.

Patent Landscape

Related Patents and Publications

The patent landscape includes other patents and publications related to acne treatments. This landscape can influence the validity and scope of the claims.

Competing Patents

Other patents may cover similar compositions or methods, which could limit the scope of the claims or even render them invalid if they are found to be anticipated or obvious in light of the prior art.

Industry Trends

The trend in acne treatment technologies can also impact the patent. For example, if newer technologies have emerged that are more effective or safer, the patent's relevance and enforceability might be diminished.

Legal Framework and Recent Developments

USPTO Guidelines and Case Law

Recent updates and guidelines from the USPTO, such as those related to the evaluation of abstract ideas and AI-assisted inventions, do not directly impact this patent since it is not related to software or AI technologies. However, general principles of patentability remain relevant[2].

Obviousness-Type Double Patenting (ODP)

In cases where multiple patents are related and claim priority from the same application, ODP analysis becomes crucial. This ensures that an inventor does not secure multiple patents for essentially the same invention, which could extend the patent term unfairly[1].

Implications for Innovators and Patent Practitioners

Strategic Considerations

For innovators and patent practitioners, understanding the claims and the patent landscape of U.S. Patent 4,507,287 is essential for developing new acne treatments that do not infringe on existing patents.

Freedom to Operate Analysis

Conducting a freedom to operate analysis can help identify potential infringement risks and guide the development of new products that are distinct from existing patented technologies[5].

Licensing and Litigation

Understanding the patent landscape also helps in negotiating licenses or preparing for potential litigation. For example, if a company wishes to use a similar composition, they may need to obtain a license or develop a non-infringing alternative.

Key Takeaways

  • Claims Analysis: The patent includes specific composition and method claims that must be evaluated for novelty and nonobviousness.
  • Prior Art Search: A thorough prior art search is essential to determine the validity of the claims.
  • Patentability Criteria: The patent must meet the criteria of utility, enablement, novelty, and nonobviousness.
  • Patent Landscape: Understanding related patents and industry trends is crucial for strategic decision-making.
  • Legal Framework: Recent USPTO guidelines and case law on patentability, though not directly applicable, provide a broader context for patent strategy.

FAQs

What is the main subject of U.S. Patent 4,507,287?

The main subject of U.S. Patent 4,507,287 is a preparation and method for the treatment of acne using a specific combination of benzoyl peroxide and sulfur.

How do you determine the novelty of a patent claim?

Novelty is determined by conducting a prior art search to identify any existing patents or publications that may anticipate the claim.

What is the difference between a prior art search and a patentability analysis?

A prior art search determines if a claim is not novel or not obvious based on discovered prior art, while a patentability analysis also considers utility and enablement requirements[5].

Why is it important to conduct a freedom to operate analysis?

A freedom to operate analysis helps identify potential infringement risks and guides the development of new products that are distinct from existing patented technologies.

How do recent USPTO guidelines impact the patentability of AI-related inventions?

Recent USPTO guidelines provide clearer frameworks for evaluating the patent eligibility of AI-related inventions, focusing on integrating judicial exceptions into practical applications and ensuring significant human contribution[2].

Cited Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit[1]
  2. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz[2]
  3. Patent Assertion Entity Activity: An FTC Study - FTC[3]
  4. Preparation and Method for the Treatment of Acne - Google Patents[4]
  5. IP: Patentability Analysis - InterSECT Job Simulations[5]

More… ↓

⤷  Subscribe

Details for Patent 4,507,287

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 June 04, 2004 4,507,287 2039-03-29
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 June 13, 2008 4,507,287 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.